VRTX241101C410000
- 63.70
- +11.10+21.10%
Vertex Pharmaceuticals Newsroom
Wells Fargo Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $555
CCORF Maintains Vertex Pharmaceuticals(VRTX.US) With Sell Rating, Cuts Target Price to $361
Scotiabank Initiates Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Announces Target Price $480
Truist Financial Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
Vertex Pharmaceuticals (VRTX) Gets a Buy From Truist Financial
Barclays Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $509
Vertex Pharmaceuticals: Hold Rating Amid Promising Developments and Pending Long-Term Validation
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $515
Piper Sandler Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $535
Piper Sandler Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $490 to $600
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $490 to $600
Optimistic Buy Rating for Vertex Pharmaceuticals Amid Promising VX-548 Developments
Vertex Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Vertex Pharmaceuticals, Maintains $600 Price Target
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Korro Bio (KRRO) and Vertex Pharmaceuticals (VRTX)
Analysts Are Neutral on These Healthcare Stocks: CVS Health (CVS), Vertex Pharmaceuticals (VRTX)
Cautious Hold on Vertex Pharmaceuticals Amidst Limited New Insights and Awaited Data
Vertex Pharmaceuticals: Strategic Growth and Promising Drug Development Drive Buy Rating
Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)